Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance
Immunohistochemical localization of programmed death-1 ligand-1 (PD-L1) in gastric carcinoma and its clinical significance
复制标题
程序性死亡1配体1（PD-L1）在胃癌中的免疫组化定位及其临床意义
DOI：
10.1016/j.acthis.2006.01.003
复制
发表时间：
2006-01-01
影响因子：
2.5
通讯作者：
Xu, Ning
中科院分区：
文献类型：
--
作者：
Wu, Changping;Zhu, Yibei;Xu, Ning
本研究通过免疫组织化学检测程序性死亡-1配体-1（PD-L1）。对102例胃癌、10例腺瘤和10例正常组织进行标记。探讨PD-L1免疫定位与胃癌临床病理特征及预后的关系。PD-L1在正常胃组织中不表达，在胃腺瘤组织中表达较弱，而在胃癌组织中表达率为42.2%。胃癌组织中PD-L1的表达与患者年龄、性别、肿瘤部位及分化程度无关。但PD-L1免疫检测与肿瘤大小、浸润深度、淋巴结转移及患者生存时间显著相关。PD-L1免疫标记显著增强（P
The present study examined programmed death-1 ligand-1 (PD-L1) detected by immunohistochemical. labeling in 102 cases of human gastric carcinoma, 10 adenoma and 10 normal tissues. The relationship between PD-L1 immunolocalization and clinical pathological features, as well as the prognosis of gastric carcinoma, was explored. There was no PD-L1 detectable in normal gastric tissues and very weak immunolabeling in gastric adenomas, but it could be detected in 42.2% of gastric carcinoma tissues. There was no correlation between PD-L1 immunolocalization and patient age, sex, tumor location or the degree of tumor differentiation in the gastric carcinomas. However, PD-L1 immunodetection was significantly correlated to tumor size, invasion, lymph node metastasis and survival time of patients. PD-L1 immunolabeling was significantly enhanced (P